Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7 Neoplasms 3 Lung Neoplasms 2 Uterine Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pleural Effusion 1 Pituitary Diseases 1 Pituitary ACTH Hypersecretion 1 Obesity 1 Myasthenia Gravis 1 Motor Activity 1 Lymphoma 1 Kidney Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Cardiotoxicity 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Advanced Solid Tumors 1 Adenocarcinoma of Lung 1 ACTH-Secreting Pituitary Adenoma 1

Interventions

Fluorouracil 498 Bevacizumab 476 Oxaliplatin 450 Leucovorin 442 Irinotecan 408 Cetuximab 318 Capecitabine 317 pembrolizumab 142 Folfox protocol 128 Panitumumab 117 regorafenib 105 Colonoscopy 88 Nivolumab 82 IFL protocol 81 Drug Therapy 77 trifluridine tipiracil drug combination 73 Radiotherapy 66 HMPL-013 65 Blood Specimen Collection 52 Gemcitabine 49 Specimen Handling 47 Standard of Care 45 Neoadjuvant Therapy 45 Magnetic Resonance Spectroscopy 44 Biopsy 44 Chemotherapy, Adjuvant 41 Trifluridine 40 atezolizumab 39 Cyclophosphamide 39 Surveys and Questionnaires 38

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Colorectal Neoplasms × Biomarkers × Clear all

NCT00855348 2014-08-04

PRESEPT

Epigenomics, Inc

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡